Sia Daneshmand, MD
Sia Daneshmand, MD, is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer.
Articles by Sia Daneshmand, MD
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
The panel shares predictions for the future of bladder cancer.
The panel discusses other exciting treatment advances in bladder cancer.
How the potential shift of new therapies to the frontline setting will impact subsequent treatment decisions.
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
The panel shared their thoughts on the EV-302 study.
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.